Skip to main content
Presentation
View our ASCO 2026 presentations by visiting our publications page

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

May 31, 2026
,
Atkins, M. et al.
ASCO
Phase II Trial
Melanoma
View Publication
All Molecules
This is some text inside of a div block.
All Conferences
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical Trials
Clear all filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AGENT-797 (Allogeneic iNKT Cell Therapy)

Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.

SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Purbhoo, et al.
No items found.
Read Now
Download Now
View Poster
INCAGN2390 (TIM-3 Antagonist)

INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.

AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Waight, et al.
No items found.
Read Now
Download Now
View Poster
INCAGN1876 (GITR Agonist)

INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization.

AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
Read Now
Download Now
View Poster
INCAGN1949 (OX40 Agonist)

INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells

AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
Read Now
Download Now
View Poster
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
Our Science
Pipeline
Publications
Clinical Trials
Immunotherapy
About BOT + BAL
Company
Our History
Our Team
Careers
Partners
Access
Patient Access
Contact Medical Affairs
Resources
Press Releases
In the News
Patient Resources
FAQs
Investors
Investor Overview
Events
Financial Information
Opt-out preferencesCookie PolicyTerms and Conditions of UsePrivacy PolicyCommunity GuidelinesAccess to Investigational Medicines PolicyReport Adverse EventInvestor Portal
© 2025 Agenus Inc. All rights reserved.